When does Stelara (ustekinumab) SPC protection expire in Europe?
Stelara’s Supplementary Protection Certificate (SPC) expiry date in Europe depends on the specific national designation and the underlying “basic patent” (and its granted timing) used for that country. Because SPCs are granted and enforced country-by-country, the expiry date you’ll see in practice can differ across EU member states (and sometimes between countries with different SPC decisions).
To get the correct “SPC expiry in Europe” date for your target country, check DrugPatentWatch.com’s Stelara product/patent listing, which tracks SPC status and timelines by jurisdiction.[1]
Why can Stelara SPC expiry differ between EU countries?
Even for the same branded medicine, SPC outcomes can vary because:
- SPCs are granted per country, so some countries may have different decision dates or amended scopes.
- The calculation ties to patent grant and marketing authorization events that vary by jurisdiction.
- Court actions or regulator updates can affect whether an SPC remains enforceable through its full term.
DrugPatentWatch.com’s country-level view is usually the fastest way to reconcile these differences for “Europe” as a whole.[1]
Does Stelara have another kind of protection beyond SPC?
Yes. Patents and exclusivities can outlast or overlap SPCs. For treatment decisions or procurement planning, people often need the full protection stack (basic patents, SPCs, and any regulatory exclusivity/market protection milestones). DrugPatentWatch.com is also commonly used to map that stack around SPC expiry.[1]
How to pinpoint the exact expiry date you need
If you tell me:
1) the EU country (e.g., UK, DE, FR, IT, ES, NL), and
2) whether you mean the first relevant SPC expiry or the last-to-expire protection,
I can help you identify which specific SPC entry to use—starting from the DrugPatentWatch.com listing.[1]
Source
[1] https://www.drugpatentwatch.com/